Literature DB >> 671172

Plasma levels, half-life values, and correlation with physiologic assays for growth and immunity.

O C Green, R J Winter, F S Kawahara, L S Phillips, P R Lewy, R L Hart, L M Pachman.   

Abstract

Plasma prednisolone levels have been measured hourly in children receiving a single dose of oral prednisone. Peak prednisolone levels occurred one to two hours after ingestion; half-life studies gave a mean value of 132 minutes in most children. Some children had marked variability in absorption and metabolism of prednisone. Somatomedin activity and cell-mediated immunity were inhibited by plasma prednisolone values which were achieved by single doses of prednisone of 0.5 mg/kg or higher. Monitoring prednisolone levels may be of value in identifying those children who accumulate excessively high levels on moderate dosage regimens.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 671172     DOI: 10.1016/s0022-3476(78)80529-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  14 in total

1.  Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study.

Authors:  Anna Carmela P Sagcal-Gironella; Catherine M T Sherwin; Rommel G Tirona; Michael J Rieder; Hermine I Brunner; Alexander A Vinks
Journal:  Clin Ther       Date:  2011-10-07       Impact factor: 3.393

2.  Pharmacokinetics of prednisolone in children with nephrosis.

Authors:  P F Miller; C J Bowmer; J Wheeldon; J T Brocklebank
Journal:  Arch Dis Child       Date:  1990-02       Impact factor: 3.791

3.  Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia.

Authors:  I Choonara; J Wheeldon; P Rayner; M Blackburn; I Lewis
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review.

Authors:  J G Gambertoglio; W J Amend; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1980-02

5.  Rifampicin-induced non-responsiveness to corticosteroid treatment in nephrotic syndrome.

Authors:  W Hendrickse; J McKiernan; M Pickup; J Lowe
Journal:  Br Med J       Date:  1979-02-03

6.  Pharmacokinetics of prednisolone in children with the nephrotic syndrome.

Authors:  M Rostin; P Barthe; G Houin; M Alvinerie; F Bouissou
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

7.  Should we stop dosing steroids per body surface area for nephrotics?

Authors:  Guido Filler; Lisa A Robinson
Journal:  Pediatr Nephrol       Date:  2015-12-28       Impact factor: 3.714

8.  Prednisolone pharmacokinetics in patients with rheumatoid arthritis, polymyalgia rheumatica and asthma.

Authors:  A J Taggart; C Astbury; J S Dixon; H A Bird
Journal:  Clin Rheumatol       Date:  1986-09       Impact factor: 2.980

9.  Duration of suppression of adrenal steroids after glucocorticoid administration.

Authors:  John S Fuqua; Deborah Rotenstein; Peter A Lee
Journal:  Int J Pediatr Endocrinol       Date:  2010-03-31

10.  Effect of inflammatory bowel disease on absorption and disposition of prednisolone.

Authors:  R L Milsap; D E George; S J Szefler; K A Murray; E Lebenthal; W J Jusko
Journal:  Dig Dis Sci       Date:  1983-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.